Saltar al contenido
Merck
Todas las fotos(1)

Documentos

D2850000

Dipyridamole

European Pharmacopoeia (EP) Reference Standard

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C24H40N8O4
Número de CAS:
58-32-2
Peso molecular:
504.63
MDL number:
MFCD00010555
UNSPSC Code:
41116107
PubChem Substance ID:
329798756
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

dipyridamole

manufacturer/tradename

EDQM

mp

165-166 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

OCCN(CCO)c1nc(N2CCCCC2)c3nc(nc(N4CCCCC4)c3n1)N(CCO)CCO

InChI

1S/C24H40N8O4/c33-15-11-31(12-16-34)23-26-20-19(21(27-23)29-7-3-1-4-8-29)25-24(32(13-17-35)14-18-36)28-22(20)30-9-5-2-6-10-30/h33-36H,1-18H2

InChI key

IZEKFCXSFNUWAM-UHFFFAOYSA-N

Gene Information

human ... PDE10A(10846) , PDE1A(5136) , PDE1B(5153) , PDE1C(5137) , PDE2A(5138) , PDE3A(5139) , PDE3B(5140) , PDE4A(5141) , PDE4B(5142) , PDE4C(5143) , PDE4D(5144) , PDE5A(8654) , PDE6A(5145) , PDE6B(5158) , PDE6C(5146) , PDE6D(5147) , PDE6G(5148) , PDE6H(5149) , PDE7A(5150) , PDE7B(27115) , PDE8A(5151) , PDE8B(8622) , PDE9A(5152) , SLC29A1(2030)

¿Está buscando productos similares? Visita Guía de comparación de productos

Categorías relacionadas

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Dipyridamole EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Selective inhibitor of phosphodiesterase V (PDE 5); potent coronary vasodilator drug; adenosine transport inhibitor; inhibitor of platelet aggregation.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Referencia del producto
Descripción
Precios

Y0000802

Dipyridamole for peak identification, European Pharmacopoeia (EP) Reference Standard

1220506

Dipyridamole, United States Pharmacopeia (USP) Reference Standard

1220517

Dipyridamole Related Compound A, United States Pharmacopeia (USP) Reference Standard

1220561

Dipyridamole Related Compound F, United States Pharmacopeia (USP) Reference Standard

1220528

Dipyridamole Related Compound B, United States Pharmacopeia (USP) Reference Standard

1220539

Dipyridamole Related Compound C, United States Pharmacopeia (USP) Reference Standard

1220540

Dipyridamole Related Compound D, United States Pharmacopeia (USP) Reference Standard

1220559

Dipyridamole Related Compound E, United States Pharmacopeia (USP) Reference Standard

BP131

Dipyridamole, British Pharmacopoeia (BP) Reference Standard

BP1102

Dipyridamole impurity standard, British Pharmacopoeia (BP) Reference Standard

Storage Class

11 - Combustible Solids

wgk_germany

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

Lo sentimos, en este momento no disponemos de COAs para este producto en línea.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

J Greenhalgh et al.
Health technology assessment (Winchester, England), 15(31), 1-178 (2011-09-06)
Occlusive vascular events such as myocardial infarction (MI), ischaemic stroke and transient ischaemic attack (TIA) are the result of a reduction in blood flow associated with an artery becoming narrow or blocked through atherosclerosis and atherothrombosis. Peripheral arterial disease is
Subrata Chakrabarti et al.
Vascular pharmacology, 48(4-6), 143-149 (2008-03-18)
Stroke is a leading cause of morbidity and mortality and the most common cause of neurological disability in older individuals. Prevention of recurrent stroke includes risk factor modification as well as the use of therapies that inhibit platelet activation. One
Djeven P Deva et al.
Cardiology in the young, 24(5), 822-830 (2013-09-21)
Vasodilator stress perfusion cardiovascular magnetic resonance imaging is a clinically useful tool for detection of clinically significant myocardial ischaemia in adults. We report our 5-year retrospective experience with perfusion cardiovascular magnetic resonance in a large, quarternary adult congenital heart disease
E L L M De Schryver et al.
The Cochrane database of systematic reviews, (2)(2), CD001820-CD001820 (2006-04-21)
Patients with limited cerebral ischaemia of arterial origin are at risk of serious vascular events (4% to 11% annually). Aspirin reduces that risk by 13%. In one trial, adding dipyridamole to aspirin was associated with a 22% risk-reduction compared with
Hyung-Hwan Kim et al.
Arteriosclerosis, thrombosis, and vascular biology, 28(3), s39-s42 (2008-01-05)
Dipyridamole (DP) is a phosphodiesterase inhibitor that increases the intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanine monophosphate (cGMP) by preventing their conversion to AMP and GMP, respectively. By increasing cAMP and cGMP levels in platelets, DP reversibly
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico